Compare JPMorgan Ultra Short Income ETF (JPST) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Medpace Holdings Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.3 (market cap $42.37B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 2.5× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Medpace Holdings Inc for 14 Days on average.
| JPST | MEDP | |
|---|---|---|
Market Cap | $42.37B | $16.82B |
Volume | 7,889,185 | 223,093 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $630.19 |
52-Week Low | $50.22 | $393.42 |
Typical Hold Time | 47 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.30 with minimal daily movement, showing stability typical of ultra-short bond funds. Technical indicators signal bearish momentum with moving averages in sell territory, though oversold RSI levels suggest potential near-term stabilization. Recent news highlights institutional position adjustments and growing investor interest in cash-alternative ETFs amid rising rate expectations.
The ETF faces headwinds from active management costs and competitive pressure from similar funds, though demand for ultrashort duration assets provides support. Key risks include interest rate sensitivity and fund flow volatility, while institutional ownership changes indicate mixed sentiment among professional investors.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
